e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Increased exhaled nitric oxide precedes lung fibrosis in a murine model of systemic sclerosis
T. Hua-Huy, N.N. Le-Dong, S. Duong-Quy, Y. Bei, S. Rivière, K.P. Tiev, C. Nicco, F. Batteux, A.T. Dinh-Xuan (Paris, France)
Source:
Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Session:
Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Session type:
Thematic Poster Session
Number:
705
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Hua-Huy, N.N. Le-Dong, S. Duong-Quy, Y. Bei, S. Rivière, K.P. Tiev, C. Nicco, F. Batteux, A.T. Dinh-Xuan (Paris, France). Increased exhaled nitric oxide precedes lung fibrosis in a murine model of systemic sclerosis. Eur Respir J 2012; 40: Suppl. 56, 705
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Panel discussion on acute decompensated pulmonary hypertension
Related content which might interest you:
Increased alveolar concentrations of exhaled nitric oxide (NO) are associated with lung affection in systemic sclerosis (SSc)
Source: Eur Respir J 2005; 26: Suppl. 49, 543s
Year: 2005
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide
Source: Eur Respir J 2007; 30: 26-30
Year: 2007
Increased inflammation in peripheral airways of patients with systemic sclerosis, measured by fractional nitric oxide
Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement
Year: 2008
Bronchial and alveolar exhaled nitric oxide as a marker of systemic involvement in patients with Crohn‘s disease
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
The source of exhaled nitric oxide does not correlate with clinical markers in interstitial lung disease
Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease
Year: 2007
Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases
Source: International Congress 2015 – IIPs: orphan
Year: 2015
Elevated levels of alveolar nitric oxide in patients with inflammatory bowel disease
Source: International Congress 2016 – Airway biomarkers
Year: 2016
Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients
Source: Eur Respir J 2001; 17: 1267-1270
Year: 2001
Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients
Source: Eur Respir J 2009; 34: 138-144
Year: 2009
Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model
Source: Eur Respir J 2006; 28: 1236-1244
Year: 2006
Nitric oxide modulates vascular remodelling in a model of chronic allergic lung inflammation
Source: Eur Respir J 2006; 28: Suppl. 50, 432s
Year: 2006
Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments
Source: Eur Respir J 2009; 34: 117-124
Year: 2009
Effect of inhaled L-arginine on airway nitric oxide in cystic fibrosis patients
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005
Role of the nitric oxide in the lung function and airway hyperreactivity in silicotic mice
Source: Annual Congress 2013 –The multiple faces of stress in lung injury
Year: 2013
iNOS-derived nitric oxide contributes to lung remodelling in an elastase-induced emphysema model
Source: Annual Congress 2010 - Proteases and the matrix
Year: 2010
Antibiotic treatment decreases exhaled nitric oxide levels in cystic fibrosis patients
Source: Eur Respir J 2004; 24: Suppl. 48, 384s
Year: 2004
Fractional exhaled nitric oxide for eosinophilic inflammation in stable COPD
Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers
Year: 2017
Increased eNO and pulmonary iNOS expression in eNOS null mice
Source: Eur Respir J 2003; 21: 770-773
Year: 2003
Use of different exhaled nitric oxide multiple flow rate models in COPD
Source: Eur Respir J 2007; 29: 651-659
Year: 2007
Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment
Source: Eur Respir J, 53 (5) 1802259; 10.1183/13993003.02259-2018
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept